Take over , buy out has been the aim from Oncosil Management for a long time now . Profitability would be nice but main aim imo is making this as enticing as possible.In 2023 Otto Buttula retired from the board as late as the AGM , or such a mutually agreed , earlier time . Once either board renewal and an adequate handover , or a potential take over can be completed . The company remains in discussions with it advisors regarding attracting a new cornerstone shareholder , or full takeover.
Brian Leedman retired from the board in 2023 . He was a co- founder of Resapp ( RAP ) and did say they would never make any money but would still be acquired ( taken over ) which it was. The current Oncosil leadership team still consist of expertise from Sirtex which was taken over for $1.9 billion and Telix Pharmaceuticals TLX , around a $ 7 billion market cap. Brian Leedman has also mentioned that , You can only have a blockbuster product if a big pharma is selling it and mentioned Sirtex as a comparison and that is the ultimate outcome for Oncosil.
Take over , buy out has been the aim from Oncosil Management for...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.050(4.42%) |
Mkt cap ! $20.33M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.15 | $1.08 | $45.62K | 40.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 718 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2361 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |